Roman Hovorka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8570422/publications.pdf

Version: 2024-02-01

312 papers	17,979 citations	18436 62 h-index	16605 123 g-index
322 all docs	322 docs citations	322 times ranked	8496 citing authors

#	Article	IF	Citations
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	1.3	69
2	Training and Support for Hybrid Closed-Loop Therapy. Journal of Diabetes Science and Technology, 2022, 16, 218-223.	1.3	21
3	Adolescentsâ€™ and their parentsâ€™ experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study. Chronic Illness, 2022, 18, 742-756.	0.6	21
4	Recent advances in closed-loop insulin delivery. Metabolism: Clinical and Experimental, 2022, 127, 154953.	1.5	16
5	Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. New England Journal of Medicine, 2022, 386, 209-219.	13.9	99
6	Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. The Lancet Healthy Longevity, 2022, 3, e135-e142.	2.0	38
7	Parentsâ€™ experiences of using remote monitoring technology to manage type 1 diabetes in very young children during a clinical trial: Qualitative study. Diabetic Medicine, 2022, 39, e14828.	1.2	12
8	Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health, 2022, 4, e245-e255.	5.9	33
9	AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial â€“ study protocol. BMC Pregnancy and Childbirth, 2022, 22, 282.	0.9	16
10	Parentsâ€™ experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: Qualitative study. Diabetes Research and Clinical Practice, 2022, 187, 109877.	1.1	9
11	Parents' views about healthcare professionals having realâ€time remote access to their young child's diabetes data: Qualitative study. Pediatric Diabetes, 2022, 23, 799-808.	1.2	7
12	Lived experience of <scp>CamAPS FX</scp> closed loop system in youth with type 1 diabetes and their parents. Diabetes, Obesity and Metabolism, 2022, 24, 2309-2318.	2.2	12
13	Estimated HbA 1c and glucose management indicator (GMI): are they the same?. Diabetic Medicine, 2021, 38, e14423.	1.2	5
14	Effect of fully automated closedâ€loop insulin delivery using faster aspart versus standard aspart on glucoâ€regulatory hormones in type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 228-233.	2.2	0
15	Resistant Starch Production and Glucose Release from Preâ€Prepared Chilled Food: The SPUD Project. Nutrition Bulletin, 2021, 46, 52-59.	0.8	6
16	Effect of nutrition on postprandial glucose control in hospitalized patients with type 2 diabetes receiving fully automated closedâ€loop insulin therapy. Diabetes, Obesity and Metabolism, 2021, 23, 234-239.	2.2	2
17	Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol. BMJ Open, 2021, 11, e042790.	0.8	10
18	New closed-loop insulin systems. Diabetologia, 2021, 64, 1007-1015.	2.9	146

#	Article	IF	Citations
19	Hybrid closedâ€loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A doubleâ€blind, multicentre, multinational, randomized, crossover study. Diabetes, Obesity and Metabolism, 2021, 23, 1389-1396.	2.2	58
20	Data Sharing While Using a Closed-Loop System: Qualitative Study of Adolescents' and Parents' Experiences and Views. Diabetes Technology and Therapeutics, 2021, 23, 500-507.	2.4	9
21	Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial. The Lancet Child and Adolescent Health, 2021, 5, 265-273.	2.7	38
22	Benefits and Challenges of Current Closed-Loop Technologies in Children and Young People With Type 1 Diabetes. Frontiers in Pediatrics, 2021, 9, 679484.	0.9	29
23	Parentsâ€™ experiences of caring for a young child with type 1 diabetes: a systematic review and synthesis of qualitative evidence. BMC Pediatrics, 2021, 21, 160.	0.7	41
24	User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care, 2021, 44, e148-e150.	4.3	12
25	Dayâ€toâ€day variability of insulin requirements in the inpatient setting: Observations during fully closedâ€loop insulin delivery. Diabetes, Obesity and Metabolism, 2021, 23, 1978-1982.	2.2	8
26	Technology in the management of type 2 diabetes: Present status and future prospects. Diabetes, Obesity and Metabolism, 2021, 23, 1722-1732.	2.2	34
27	214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised Trial. Diabetes, 2021, 70, 214-OR.	0.3	2
28	Adolescentsâ€™ Experiences of Using a Smartphone Application Hosting a Closed-loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study. Journal of Diabetes Science and Technology, 2021, 15, 1042-1051.	1.3	9
29	Closedâ€loop technology: a practical guide. Practical Diabetes, 2021, 38, 33-39.	0.1	10
30	Optimizing the use of technology to support people with diabetes: research recommendations from Diabetes UKâ€™s 2019 diabetes and technology workshop. Diabetic Medicine, 2021, 38, e14647.	1.2	2
31	Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes â€“ Baseline Assessment. Frontiers in Endocrinology, 2021, 12, 721028.	1.5	5
32	Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nature Medicine, 2021, 27, 1471-1476.	15.2	38
33	Continuous glucose monitoring in extremely preterm infants in intensive care: the REACT RCT and pilot study of â€˜closed-loopâ€™ technology. Efficacy and Mechanism Evaluation, 2021, 8, 1-142.	0.9	1
34	Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index. Journal of Diabetes Science and Technology, 2020, 14, 277-283.	1.3	20
35	Novel Single-Site Device for Conjoined Glucose Sensing and Insulin Infusion: Performance Evaluation in Diabetes Patients During Home-Use. IEEE Transactions on Biomedical Engineering, 2020, 67, 323-332.	2.5	10
36	Who Should Access Closed-Loop Technology? A Qualitative Study of Clinician Attitudes in England. Diabetes Technology and Therapeutics, 2020, 22, 404-410.	2.4	14

#	Article	IF	Citations
37	Automated Insulin Delivery in Adults. Endocrinology and Metabolism Clinics of North America, 2020, 49, 167-178.	1.2	17
38	Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. Journal of Diabetes Science and Technology, 2020, 14, 1035-1064.	1.3	77
39	The artificial pancreas. Current Opinion in Organ Transplantation, 2020, Publish Ahead of Print, 336-342.	0.8	22
40	Health professionals' views about who would benefit from using a closedâ€loop system: a qualitative study. Diabetic Medicine, 2020, 37, 1030-1037.	1.2	38
41	Does eating a reheated starchy carbohydrate meal improve postprandial glycaemia?. Proceedings of the Nutrition Society, 2020, 79, .	0.4	1
42	COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare?. Journal of Diabetes Science and Technology, 2020, 14, 735-736.	1.3	11
43	Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 691-696.	2.4	3
44	Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy. Expert Review of Medical Devices, 2020, 17, 707-720.	1.4	52
45	Closed-loop insulin delivery system enhances type 1 diabetes glycemic control. Journal of Pediatrics, 2020, 218, 259-262.	0.9	1
46	What Training, Support, and Resourcing Do Health Professionals Need to Support People Using a Closed-Loop System? A Qualitative Interview Study with Health Professionals Involved in the Closed Loop from Onset in Type 1 Diabetes (CLOuD) Trial. Diabetes Technology and Therapeutics, 2020, 22, 468-475.	2.4	19
47	A qualitative study of clinician attitudes towards closedâ€loop systems in mainstream diabetes care in England. Diabetic Medicine, 2020, 37, 1023-1029.	1.2	14
48	Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care, 2020, 43, e38-e39.	4.3	14
49	Feasibility of automated insulin delivery guided by continuous glucose monitoring in preterm infants. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 279-284.	1.4	27
50	Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol. BMJ Open, 2020, 10, e033500.	0.8	14
51	Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?. Annals of Translational Medicine, 2020, 8, 1535.	0.7	0
52	Shortâ€term fully closedâ€loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2718-2722.	2.2	13
53	The importance of prandial insulin bolus timing with hybrid closedâ€loop systems. Diabetic Medicine, 2019, 36, 1716-1717.	1.2	15
54	Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial. Diabetes Care, 2019, 42, 594-600.	4.3	79

#	Article	IF	Citations
55	Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 359-368.	1.8	19
56	Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery. Diabetes Care, 2019, 42, 1344-1347.	4.3	51
57	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	4.3	2,101
58	Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol. BMJ Open, 2019, 9, e027856.	0.8	14
59	Reduced burden of diabetes and improved quality of life: Experiences from unrestricted dayâ€andâ€night hybrid closedâ€loop use in very young children with type 1 diabetes. Pediatric Diabetes, 2019, 20, 794-799.	1.2	72
60	Closedâ€loop insulin delivery in endâ€ofâ€life care: a case report. Diabetic Medicine, 2019, 36, 1711-1714.	1.2	4
61	Broadening the Debate About Post-trial Access to Medical Interventions: A Qualitative Study of Participant Experiences at the End of a Trial Investigating a Medical Device to Support Type 1 Diabetes Self-Management. AJOB Empirical Bioethics, 2019, 10, 100-112.	0.8	19
62	Advances in artificial pancreas systems. Science Translational Medicine, 2019, 11, .	5.8	46
63	Fully closed-loop insulin delivery improves glucoseÂcontrol of inpatients with type 2 diabetesÂreceiving hemodialysis. Kidney International, 2019, 96, 593-596.	2.6	51
64	Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 368-377.	5.5	59
65	Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: Potential advantage? A randomized cross-over trial. PLoS ONE, 2019, 14, e0212013.	1.1	6
66	Participants' Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study. Diabetes Technology and Therapeutics, 2019, 21, 119-127.	2.4	52
67	Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data. Diabetes Care, 2019, 42, e60-e61.	4.3	17
68	Closed-loop management of inpatient hyperglycaemia. British Journal of Hospital Medicine (London,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	1
69	Is an artificial pancreas (closedâ€loop system) for Type 1 diabetes effective?. Diabetic Medicine, 2019, 36, 279-286.	1.2	72
70	The impact of using a closedâ€loop system on food choices and eating practices among people with Type 1 diabetes: a qualitative study involving adults, teenagers and parents. Diabetic Medicine, 2019, 36, 753-760.	1.2	32
71	Mixedâ€meal tolerance test to assess residual betaâ€cell secretion: Beyond the areaâ€underâ€curve of plasma Câ€peptide concentration. Pediatric Diabetes, 2019, 20, 282-285.	1.2	12
72	1039-P: Hybrid Closed-Loop in Adults with Type 1 Diabetes: Impact of Baseline A1c on Glucose Outcomes and Insulin Delivery. Diabetes, 2019, 68, 1039-P.	0.3	0

#	Article	IF	Citations
73	1047-P: Can Closed-Loop Overcome High Day-to-Day Variability of Insulin Needs in Inpatients on General Wards?. Diabetes, 2019, 68, .	0.3	0
74	1046-P: Day-to-Day Variability of Insulin Requirements in Inpatients on General Wards. Diabetes, 2019, 68, .	0.3	0
75	79-OR: Fully Closed-Loop Using Faster vs. Standard Aspart in Type 2 Diabetes (T2D): A Double-Blind Randomised Crossover Trial. Diabetes, 2019, 68, .	0.3	0
76	115-LB: Optimal Sampling Duration of Hybrid Closed-Loop Therapy to Determine Long-Term Glycemic Control in Adults with Type 1 Diabetes. Diabetes, 2019, 68, .	0.3	0
77	Closed-loop management of inpatient hyperglycemia. Aging, 2019, 11, 5292-5293.	1.4	0
78	Hypoglycaemia incidence and recovery during home use of hybrid closedâ€loop insulin delivery in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2004-2008.	2.2	19
79	Bridging technology and clinical practice: innovating inpatient hyperglycaemia management in nonâ€critical care settings. Diabetic Medicine, 2018, 35, 460-471.	1.2	16
80	Glucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story. International Journal of Pharmaceutics, 2018, 544, 309-318.	2.6	28
81	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 361, k1310.	2.4	294
82	Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care, 2018, 41, 1391-1399.	4.3	113
83	Bolusing frequency and amount impacts glucose control during hybrid closedâ€loop. Diabetic Medicine, 2018, 35, 347-351.	1.2	6
84	Closed-Loop Insulin for Glycemic Control in Noncritical Care. New England Journal of Medicine, 2018, 379, 1970-1971.	13.9	8
85	Womenâ€™s Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy. Journal of Diabetes Science and Technology, 2018, 12, 1125-1131.	1.3	32
86	Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet, The, 2018, 392, 1321-1329.	6.3	302
87	Technology in the management of type 1 diabetes mellitus â€” current status and future prospects. Nature Reviews Endocrinology, 2018, 14, 464-475.	4.3	103
88	Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Diabetes Technology and Therapeutics, 2018, 20, 501-505.	2.4	23
89	Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. New England Journal of Medicine, 2018, 379, 547-556.	13.9	144
90	Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas. Critical Care, 2018, 22, 182.	2.5	42

#	Article	IF	Citations
91	Patientsâ€™ and caregiversâ€™ experiences of using continuous glucose monitoring to support diabetes self-management: qualitative study. BMC Endocrine Disorders, 2018, 18, 12.	0.9	102
92	Fully Closed-Loop Glucose Control in Noncritical Care Settingsâ€”A Randomised, Controlled Two-Centre Study. Diabetes, 2018, 67, 350-OR.	0.3	0
93	Looking Beyond HbA1câ€”Evaluating Glycaemic Control during Closed-Loop Use in Type 1 Diabetes. Diabetes, 2018, 67, .	0.3	0
94	A Novel Composite Glucose Index (COGI) for Evaluating Closed-Loop Performance in Type 1 Diabetes. Diabetes, 2018, 67, .	0.3	1
95	Adaptability of Closed-Loop during Labor, Delivery, and Postpartumâ€”A Secondary Analysis of Data From Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Diabetes, 2018, 67, .	0.3	0
96	Rapid Benefits of Structured Optimization and Sensor-Augmented Insulin Pump Therapy in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 180-181.	1.3	3
97	Modelling the effect of insulin on the disposal of meal-attributable glucose in type 1 diabetes. Medical and Biological Engineering and Computing, 2017, 55, 271-282.	1.6	6
98	Closed-loop for type 1 diabetes â€“ an introduction and appraisal for the generalist. BMC Medicine, 2017, 15, 14.	2.3	29
99	Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes and Endocrinology,the, 2017, 5, 261-270.	5.5	120
100	Faster insulin action is associated with improved glycaemic outcomes during closedâ€loop insulin delivery and sensorâ€augmented pump therapy in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1485-1489.	2.2	7
101	Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. Journal of Diabetes Science and Technology, 2017, 11, 1080-1088.	1.3	99
102	Finding the right route for insulin delivery â€“ an overview of implantable pump therapy. Expert Opinion on Drug Delivery, 2017, 14, 1103-1111.	2.4	26
103	Cover Image, Volume 19, Issue 10. Diabetes, Obesity and Metabolism, 2017, 19, i-i.	2.2	0
104	Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes. Expert Opinion on Drug Delivery, 2017, 14, 1367-1377.	2.4	4
105	Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets. Clinical Science, 2017, 131, 2561-2573.	1.8	31
106	Sensor mightier than pumpâ€”the jury is still out. Lancet Diabetes and Endocrinology,the, 2017, 5, 672-673.	5.5	0
107	Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. BMJ Open, 2017, 7, e016738.	0.8	13
108	International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017, 40, 1631-1640.	4.3	1,376

#	Article	IF	Citations
109	Experiences of closedâ€loop insulin delivery among pregnant women with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1461-1469.	1.2	44
110	Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 117-124.	5.5	91
111	Glucose Monitoring and Insulin Pump Therapy in the Management of Children and Adolescents with Type 1 Diabetes. , 2017, , 163-172.		0
112	Modeling Day-to-Day Variability of Glucoseâ€“Insulin Regulation Over 12-Week Home Use of Closed-Loop Insulin Delivery. IEEE Transactions on Biomedical Engineering, 2017, 64, 1412-1419.	2.5	52
113	Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial. Journal of Diabetes Science and Technology, 2017, 11, 513-521.	1.3	3
114	Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 433-437.	2.4	11
115	Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia, 2016, 59, 1795-1805.	2.9	187
116	Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 2016, 39, 1175-1179.	4.3	195
117	Factors Affecting Recruitment of Participants for Studies of Diabetes Technology in Newly Diagnosed Youth with Type 1 Diabetes: A Qualitative Focus Group Study with Parents and Children. Diabetes Technology and Therapeutics, 2016, 18, 568-573.	2.4	3
118	Closed-Loop Insulin Delivery During Pregnancy in Women With Type 1 Diabetes. Obstetrical and Gynecological Survey, 2016, 71, 699-701.	0.2	0
119	The use of closed loop in outpatient/home studies. Diabetes Research and Clinical Practice, 2016, 120, S21.	1.1	0
120	Glucose Control in the ICU. Journal of Diabetes Science and Technology, 2016, 10, 1372-1381.	1.3	64
121	Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. Diabetes Care, 2016, 39, 2019-2025.	4.3	65
122	Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine, 2016, 375, 644-654.	13.9	203
123	Available at a flash: a new way to check glucose. Lancet, The, 2016, 388, 2213-2214.	6.3	3
124	Role of Dual-Hormone Closed-Loop Delivery System in the Future. Diabetes Technology and Therapeutics, 2016, 18, 452-454.	2.4	0
125	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2016, 18, S-86-S-100.	2.4	2
126	Closing the Loop. Diabetes Technology and Therapeutics, 2016, 18, S-29-S-42.	2.4	9

#	Article	IF	Citations
127	Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes. Diabetes Care, 2016, 39, 830-832.	4.3	49
128	Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Diabetes Care, 2016, 39, 1168-1174.	4.3	105
129	Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opinion on Drug Delivery, 2016, 13, 389-400.	2.4	45
130	Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes/Metabolism Research and Reviews, 2016, 32, 21-39.	1.7	115
131	Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1346-1347.	1.3	6
132	Rapid model exploration for complex hierarchical data: application to pharmacokinetics of insulin aspart. Statistics in Medicine, 2015, 34, 3144-3158.	0.8	7
133	Safety, efficacy and glucose turnover of reduced prandial boluses during closedâ€loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes, Obesity and Metabolism, 2015, 17, 1173-1179.	2.2	19
134	Psychosocial aspects of closedâ€and openâ€loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. Diabetic Medicine, 2015, 32, 601-608.	1.2	91
135	Quantifying the Acute Changes in Glucose with Exercise in Type 1 Diabetes: A Systematic Review and Meta-Analysis. Sports Medicine, 2015, 45, 587-599.	3.1	83
136	Closing the Loop. Diabetes Technology and Therapeutics, 2015, 17, S-27-S-38.	2.4	0
137	A diet low in sugar reduces the production of atherogenic lipoproteins in men with high liver fat. Atherosclerosis, 2015, 241, e46.	0.4	2
138	Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3â€“6Âyears with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. Diabetologia, 2015, 58, 687-690.	2.9	18
139	Modelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery. BioMedical Engineering OnLine, 2015, 14, 19.	1.3	11
140	Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. Lancet, The, 2015, 385, S96.	6.3	18
141	Holistic Impact of Closed-Loop Technology on People With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 932-933.	1.3	16
142	Artificial Pancreas Project at Cambridge 2013. Diabetic Medicine, 2015, 32, 987-992.	1.2	15
143	Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions. Diabetes Technology and Therapeutics, 2015, 17, 801-807.	2.4	33
144	Unsupervised home use of an overnight closedâ€loop system over 3â€“4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 452-458.	2.2	26

#	Article	IF	Citations
145	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2015, 17, S-96-S-108.	2.4	1
146	Perioperative Tight Glucose Control Reduces Postoperative Adverse Events in Nondiabetic Cardiac Surgery Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3081-3089.	1.8	67
147	Home Use of an Artificial Beta Cell in Type 1 Diabetes. New England Journal of Medicine, 2015, 373, 2129-2140.	13.9	397
148	The Future of the Artificial Pancreas. Diabetes Technology and Therapeutics, 2015, 17, 763-765.	2.4	3
149	Response to Mitre et al.: â€œAnalysis of Continuous Glucose Monitoring Data to Assess Outpatient Closed-Loop Studies: Considerations for Different Sensorsâ€• Diabetes Technology and Therapeutics, 2014, 16, 328-329.	2.4	0
150	Comment on Doyle et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. Diabetes Care 2014;37:1191â€“1197. Diabetes Care, 2014, 37, e226-e227.	4.3	8
151	Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study. Diabetes Care, 2014, 37, 1931-1937.	4.3	113
152	Pharmacokinetics of Insulin Aspart in Pregnant Women With Type 1 Diabetes: Every Day Is Different. Diabetes Care, 2014, 37, e121-e122.	4.3	32
153	Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3â€“6â€…years: comparison between diluted and standard insulin strength. BMJ Open Diabetes Research and Care, 2014, 2, e000040.	1.2	31
154	Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open, 2014, 4, e006075-e006075.	0.8	12
155	Glucose Control in the Intensive Care Unit by Use of Continuous Glucose Monitoring: What Level of Measurement Error Is Acceptable?. Clinical Chemistry, 2014, 60, 1500-1509.	1.5	30
156	Evaluating the Performance of a Novel Embedded Closed-loop System. Journal of Diabetes Science and Technology, 2014, 8, 267-272.	1.3	7
157	Bringing closed-loop home. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 95-101.	1.2	18
158	Lipohypertrophy and the Artificial Pancreas. Journal of Diabetes Science and Technology, 2014, 8, 915-917.	1.3	13
159	Feasibility of Closed-Loop Insulin Delivery in Type 2 Diabetes: A Randomized Controlled Study. Diabetes Care, 2014, 37, 1198-1203.	4.3	49
160	Glucose control in nonâ€critically ill inpatients with diabetes: towards closedâ€loop. Diabetes, Obesity and Metabolism, 2014, 16, 500-509.	2.2	15
161	Accuracy of Subcutaneous Continuous Glucose Monitoring in Critically Ill Adults: Improved Sensor Performance with Enhanced Calibrations. Diabetes Technology and Therapeutics, 2014, 16, 97-101.	2.4	38
162	Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Research and Care, 2014, 2, e000025.	1.2	132

#	Article	IF	Citations
163	Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Diabetes Care, 2014, 37, 1204-1211.	4.3	193
164	Insulin pump therapy in youth with type 1 diabetes: toward closed-loop systems. Expert Opinion on Drug Delivery, 2014, 11, 943-955.	2.4	19
165	Safety of closedâ€loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes, Obesity and Metabolism, 2014, 16, 1174-1178.	2.2	29
166	Closing the Loop. Diabetes Technology and Therapeutics, 2014, 16, S-23-S-33.	2.4	5
167	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2014, 16, S-100-S-109.	2.4	0
168	Self-Monitoring of Blood Glucoseâ€"An Overview. Diabetes Technology and Therapeutics, 2014, 16, S-3-S-10.	2.4	5
169	Continuous glucose control in the ICU: report of a 2013 round table meeting. Critical Care, 2014, 18, 226.	2.5	68
170	Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery. Computer Methods and Programs in Biomedicine, 2014, 117, 298-307.	2.6	5
171	Glucose Turnover After Replacement of Usual Therapy by Insulin in Insulin-naive Type 2 Diabetes Subjects. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2225-2232.	1.8	5
172	Glucose control in intensive care: usability, efficacy and safety of Space GlucoseControl in two medical European intensive care units. BMC Endocrine Disorders, 2014, 14, 62.	0.9	17
173	Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes and Endocrinology,the, 2014, 2, 701-709.	5.5	140
174	Prandial Hypertriglyceridemia in Metabolic Syndrome Is Due to an Overproduction of Both Chylomicron and VLDL Triacylglycerol. Diabetes 2013;62:4063-4069. Diabetes, 2014, 63, 815-815.	0.3	0
175	Simulation Models for In-Silico Evaluation of Closed-Loop Insulin Delivery Systems in Type 1 Diabetes. Lecture Notes in Bioengineering, 2014, , 131-149.	0.3	4
176	Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. Diabetologia, 2013, 56, 1108-1117.	2.9	37
177	Evaluating the Accuracy and Large Inaccuracy of Two Continuous Glucose Monitoring Systems. Diabetes Technology and Therapeutics, 2013, 15, 143-149.	2.4	40
178	Accuracy of Continuous Glucose Monitoring During Exercise in Type 1 Diabetes Pregnancy. Diabetes Technology and Therapeutics, 2013, 15, 223-229.	2.4	30
179	Assessing Performance of Closed-Loop Insulin Delivery Systems by Continuous Glucose Monitoring: Drawbacks and Way Forward. Diabetes Technology and Therapeutics, 2013, 15, 4-12.	2.4	48
180	Stochastic Virtual Population of Subjects With Type 1 Diabetes for the Assessment of Closed-Loop Glucose Controllers. IEEE Transactions on Biomedical Engineering, 2013, 60, 3524-3533.	2.5	49

#	Article	IF	Citations
181	Prandial Hypertriglyceridemia in Metabolic Syndrome Is Due to an Overproduction of Both Chylomicron and VLDL Triacylglycerol. Diabetes, 2013, 62, 4063-4069.	0.3	47
182	Pharmacokinetics of Insulin Aspart in Pump-Treated Subjects With Type 1 Diabetes: Reproducibility and Effect of Age, Weight, and Duration of Diabetes. Diabetes Care, 2013, 36, e173-e174.	4.3	47
183	Day and Night Closed-Loop Control in Adults With Type 1 Diabetes. Diabetes Care, 2013, 36, 3882-3887.	4.3	95
184	Physical Activity Energy Expenditure and Glucose Control in Pregnant Women With Type 1 Diabetes. Diabetes Care, 2013, 36, 1095-1101.	4.3	22
185	Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes. Diabetes Care, 2013, 36, 838-844.	4.3	144
186	Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations. American Journal of Transplantation, 2013, 13, 3236-3243.	2.6	55
187	Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Critical Care, 2013, 17, R159.	2.5	94
188	Closing the Loop. Diabetes Technology and Therapeutics, 2013, 15, S-29-S-39.	2.4	4
189	Continuous glucose monitoring in critically ill adults: comparison of two different calibration protocols. Critical Care, 2013, 17, .	2.5	1
190	Clinical review: Consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults. Critical Care, 2013, 17, 229.	2.5	169
191	The Use of Continuous Glucose Monitoring Combined with Computer-Based eMPC Algorithm for Tight Glucose Control in Cardiosurgical ICU. BioMed Research International, 2013, 2013, 1-8.	0.9	42
192	A novel method for measuring intestinal and hepatic triacylglycerol kinetics. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1041-E1047.	1.8	9
193	Plasma Câ€peptide concentration in women with Typeâ€ƒ1 diabetes during early and late pregnancy. Diabetic Medicine, 2012, 29, e361-4.	1.2	10
194	Validity of triple- and dual-tracer techniques to estimate glucose appearance. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E1493-E1501.	1.8	18
195	Artificial pancreas: the bridge to a cure for type 1 diabetes. European Diabetes Nursing, 2012, 9, 56-60.	0.2	2
196	Closed-Loop Insulin Delivery in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 2012, 41, 105-117.	1.2	64
197	Efficacy and Safety of Glucose Control with Space GlucoseControl in the Medical Intensive Care Unitâ€"An Open Clinical Investigation. Diabetes Technology and Therapeutics, 2012, 14, 690-695.	2.4	27
198	Estimating postprandial glucose fluxes using hierarchical Bayes modelling. Computer Methods and Programs in Biomedicine, 2012, 108, 102-112.	2.6	11

#	Article	IF	Citations
199	Gender Differences in VLDL₁and VLDL₂Triglyceride Kinetics and Fatty Acid Kinetics in Obese Postmenopausal Women and Obese Men. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2475-2481.	1.8	15
200	Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatric Diabetes, 2012, 13, 449-453.	1.2	48
201	Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. Diabetologia, 2012, 55, 282-293.	2.9	85
202	Closed-loop insulin delivery: towards improved diabetes care. Discovery Medicine, 2012, 13, 159-70.	0.5	25
203	Evaluating Glycemic Control Algorithms by Computer Simulations. Diabetes Technology and Therapeutics, 2011, 13, 713-722.	2.4	24
204	Closed-loop in children with type 1 diabetes: Specific challenges. Diabetes Research and Clinical Practice, 2011, 93, S131-S135.	1.1	5
205	Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ: British Medical Journal, 2011, 342, d1855-d1855.	2.4	217
206	Automated Overnight Closed-Loop Glucose Control in Young Children with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 419-424.	2.4	52
207	Closed-loop insulin delivery for treatment of type 1 diabetes. BMC Medicine, 2011, 9, 120.	2.3	82
208	Technological advances in pregnancy complicated by type 1 diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 104.	0.2	0
209	Fitting dynamic models with forcing functions: Application to continuous glucose monitoring in insulin therapy. Statistics in Medicine, 2011, 30, 2234-2250.	0.8	32
210	A Stepwise Approach toward Closed-Loop Blood Glucose Control for Intensive Care Unit Patients: Results from a Feasibility Study in Type 1 Diabetic Subjects Using Vascular Microdialysis with Infrared Spectrometry and a Model Predictive Control Algorithm. Journal of Diabetes Science and Technology, 2011, 5, 901-905.	1.3	11
211	Meta-Analysis of Overnight Closed-Loop Randomized Studies in Children and Adults with Type 1 Diabetes: The Cambridge Cohort. Journal of Diabetes Science and Technology, 2011, 5, 1352-1362.	1.3	20
212	Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes. Diabetes Care, 2011, 34, 2527-2529.	4.3	101
213	Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes. Diabetes Care, 2011, 34, 406-411.	4.3	115
214	Closed-loop insulin delivery: from bench to clinical practice. Nature Reviews Endocrinology, 2011, 7, 385-395.	4.3	274
215	Measurement delay associated with the GuardianÂ® RT continuous glucose monitoring system. Diabetic Medicine, 2010, 27, 117-122.	1.2	20
216	Suspended insulin infusion during overnight closedâ€loop glucose control in children and adolescents with Typeâ€ƒ1 diabetes. Diabetic Medicine, 2010, 27, 480-484.	1.2	37

#	Article	IF	Citations
217	Simulation Environment to Evaluate Closed-Loop Insulin Delivery Systems in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2010, 4, 132-144.	1.3	195
218	Treatment with Recombinant Human Insulin-Like Growth Factor (rhIGF)-I/rhIGF Binding Protein-3 Complex Improves Metabolic Control in Subjects with Severe Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2113-2122.	1.8	50
219	Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet, The, 2010, 375, 743-751.	6.3	429
220	Hospital Glucose Control: Safe and Reliable Glycemic Control Using Enhanced Model Predictive Control Algorithm in Medical Intensive Care Unit Patients. Diabetes Technology and Therapeutics, 2010, 12, 405-412.	2.4	23
221	Parental Attitudes Towards Overnight Closed-Loop Glucose Control in Children with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2010, 12, 35-39.	2.4	44
222	Progress with Closed-loop Systems in Type 1 Diabetes. European Endocrinology, 2010, 6, 31.	0.8	0
223	Overnight Closed-Loop Insulin Delivery with Model Predictive Control: Assessment of Hypoglycemia and Hyperglycemia Risk Using Simulation Studies. Journal of Diabetes Science and Technology, 2009, 3, 1109-1120.	1.3	58
224	Glycemic Variability Correlates Strongly With PostprandialÎ²-Cell Dysfunction in a Segment of Type 2 Diabetic Patients Using Oral Hypoglycemic Agents. Diabetes Care, 2009, 32, 1058-1062.	4.3	99
225	Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients. Diabetes Care, 2009, 32, 757-761.	4.3	90
226	Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E454-E461.	1.8	38
227	Intensive insulin therapy: enhanced Model Predictive Control algorithm versus standard care. Intensive Care Medicine, 2009, 35, 123-128.	3.9	525
228	Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabetic Medicine, 2009, 26, 532-539.	1.2	14
229	Artificial pancreas: an emerging approach to treat Type 1 diabetes. Expert Review of Medical Devices, 2009, 6, 401-410.	1.4	50
230	Effect of delay on measurement of blood glucose levels in young subjects with type 1 diabetes. Diabetes Research and Clinical Practice, 2009, 86, e31-e33.	1.1	3
231	Tight glycaemic control by an automated algorithm with time-variant sampling in medical ICU patients. Intensive Care Medicine, 2008, 34, 1224-1230.	3.9	87
232	A simulation model of glucose regulation in the critically ill. Physiological Measurement, 2008, 29, 959-978.	1.2	86
233	Simulation models for in silico testing of closed-loop glucose controllers in type 1 diabetes. Drug Discovery Today: Disease Models, 2008, 5, 289-298.	1.2	38
234	In Silico Testingâ€"Impact on the Progress of the Closed Loop Insulin Infusion for Critically Ill Patients Project. Journal of Diabetes Science and Technology, 2008, 2, 417-423.	1.3	28

#	Article	IF	Citations
235	Further Development of Artificial Pancreas: Blocked by Patents?. Journal of Diabetes Science and Technology, 2008, 2, 971-976.	1.3	4
236	Insulin Administration and Rate of Glucose Appearance in People With Type 1 Diabetes. Diabetes Care, 2008, 31, 2183-2187.	4.3	18
237	Evaluation of Implementation of a Fully Automated Algorithm (Enhanced Model Predictive Control) in an Interacting Infusion Pump System for Establishment of Tight Glycemic Control in Medical Intensive Care Unit Patients. Journal of Diabetes Science and Technology, 2008, 2, 963-970.	1.3	22
238	The Future of Continuous Glucose Monitoring: Closed Loop. Current Diabetes Reviews, 2008, 4, 269-279.	0.6	69
239	Parenteral Glucose and Glucose Control in the Critically Ill: A Kinetic Appraisal. Journal of Diabetes Science and Technology, 2007, 1, 357-365.	1.3	5
240	Calculating glucose fluxes during meal tolerance test: a new computational approach. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E610-E619.	1.8	23
241	Blood Glucose Control by a Model Predictive Control Algorithm with Variable Sampling Rate Versus a Routine Glucose Management Protocol in Cardiac Surgery Patients: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2960-2964.	1.8	98
242	Intense Exercise in Type 1 Diabetes: Exploring the Role of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2007, 1, 570-573.	1.3	13
243	The artificial pancreas: making headway. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 56-58.	0.2	8
244	Automated Glucose Control in the ICU: Effect of Nutritional Protocol and Measurement Error. , 2006, 2006, 67-70.		12
245	Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E167-E174.	1.8	25
246	Roadmap to the artificial pancreas. Diabetes Research and Clinical Practice, 2006, 74, S178-S182.	1.1	34
247	TIME-VARIANT INSULIN SENSITIVITY IN CRITICALLY ILL SUBJECTS. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2006, 39, 458-462.	0.4	0
248	Continuous glucose monitoring and closed-loop systems. Diabetic Medicine, 2006, 23, 1-12.	1.2	371
249	On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes. Diabetic Medicine, 2006, 23, 90-93.	1.2	50
250	Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans. Journal of Lipid Research, 2006, 47, 975-981.	2.0	13
251	Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients: Response to Ligtenberg et al.. Diabetes Care, 2006, 29, 1987-1988.	4.3	16
252	Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients. Diabetes Care, 2006, 29, 271-276.	4.3	189

#	Article	IF	Citations
253	Insulin Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting Insulin. IEEE Transactions on Biomedical Engineering, 2005, 52, 3-12.	2.5	209
254	Management of diabetes using adaptive control. International Journal of Adaptive Control and Signal Processing, 2005, 19, 309-325.	2.3	49
255	Grading System to Assess Clinical Performance of Closed-Loop Glucose Control. Diabetes Technology and Therapeutics, 2005, 7, 72-82.	2.4	14
256	Evaluation of glucose controllers in virtual environment: methodology and sample application. Artificial Intelligence in Medicine, 2004, 32, 171-181.	3.8	54
257	Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiological Measurement, 2004, 25, 905-920.	1.2	1,025
258	Closing the Loop: The Adicol Experience. Diabetes Technology and Therapeutics, 2004, 6, 307-318.	2.4	131
259	Population and individual minimal modeling of the frequently sampled insulin-modified intravenous glucose tolerance test. Metabolism: Clinical and Experimental, 2004, 53, 1349-1354.	1.5	23
260	Interstitial glucose kinetics in subjects with type 1 diabetes under physiologic conditions. Metabolism: Clinical and Experimental, 2004, 53, 1484-1491.	1.5	24
261	Relation between insulin kinetics and insulin sensitivity in pregnancy. European Journal of Clinical Investigation, 2003, 33, 698-703.	1.7	11
262	Bayesian hierarchical approach to estimate insulin sensitivity by minimal model. Clinical Science, 2003, 105, 551-560.	1.8	25
263	Evaluation of cold two compartment minimal model in type 2 diabetes. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 445-450.	0.4	0
264	Reduced sampling protocols with Bayesian hierarchical analysis during minimal model of IVGTT. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 421-425.	0.4	0
265	Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E992-E1007.	1.8	297
266	Associations of Glucose Control with Insulin Sensitivity and Pancreatic Î²-Cell Responsiveness in Newly Presenting Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 198-203.	1.8	18
267	Associations of Glucose Control with Insulin Sensitivity and Pancreatic Â-Cell Responsiveness in Newly Presenting Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 198-203.	1.8	14
268	Relationship between Î²-cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting Type 2 diabetes. Diabetic Medicine, 2001, 18, 797-802.	1.2	4
269	IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes, 2000, 49, 789-796.	0.3	42
270	Insulin sensitivity of glucose transport and glucose disposal during IVGTT. Diabetes Research and Clinical Practice, 2000, 50, 163.	1.1	0

#	Article	IF	Citations
271	A surrogate measure of whole body leucine transport across the cell membrane. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E573-E579.	1.8	1
272	Dynamic updating in DIAS-NIDDM and DIAS causal probabilistic networks. IEEE Transactions on Biomedical Engineering, 1999, 46, 158-168.	2.5	9
273	Estimating Protein Turnover with a [13N,15C]Leucine Tracer: a Study Using Simulated Data. Journal of Theoretical Biology, 1999, 198, 165-172.	0.8	3
274	Preliminary experience of the DIAS computer model in providing insulin dose advice to patients with insulin dependent diabetes. Computer Methods and Programs in Biomedicine, 1998, 56, 157-164.	2.6	26
275	Using a double blind controlled clinical trial to evaluate the function of a Diabetes Advisory System: a feasible approach?. Computer Methods and Programs in Biomedicine, 1998, 56, 165-173.	2.6	18
276	DIASâ€“NIDDMâ€”a model-based decision support system for insulin dose adjustment in insulin-treated subjects with NIDDM. Computer Methods and Programs in Biomedicine, 1998, 56, 175-192.	2.6	14
277	CODE: a deconvolution program implementing a regularization method of deconvolution constrained to non-negative values. Description and pilot evaluation. , 1998, 19, 39-53.		21
278	Reproducibility and comparability of insulin sensitivity indices measured by stable-label intravenous glucose tolerance test. , 1998, 15, 234-246.		13
279	Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia, 1998, 41, 548-554.	2.9	52
280	Pancreatic Î²-Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 744-750.	1.8	73
281	Modelling and decision support in physiology and medicine: a methodological framework with Illustration. Mathematical and Computer Modelling of Dynamical Systems, 1998, 4, 73-99.	1.4	2
282	CODE: a deconvolution program implementing a regularization method of deconvolution constrained to non-negative values. Description and pilot evaluation. , 1998, 19, 39.		1
283	Pancreatic Â-Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 744-750.	1.8	59
284	A Dynamic Model of Carbon Dioxide Transport in the Blood. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1997, 30, 57-62.	0.4	1
285	Constant infusion and bolus injection of stable-label tracer give reproducible and comparable fasting HGO. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E192-E201.	1.8	7
286	Computer simulation in clinical practice. International Journal of Medical Informatics, 1997, 45, 129-130.	1.6	0
287	DIASâ€”the diabetes advisory system: an outline of the system and the evaluation results obtained so far. Computer Methods and Programs in Biomedicine, 1997, 54, 49-58.	2.6	33
288	A comparison of six deconvolution techniques. Journal of Pharmacokinetics and Pharmacodynamics, 1996, 24, 283-299.	0.6	55

#	Article	IF	Citations
289	Analysing the hypoglycaemic counter-regulation: a clinically relevant phenomenon?. Computer Methods and Programs in Biomedicine, 1996, 50, 231-240.	2.6	14
290	Use of the DIAS model to predict unrecognised hypoglycaemia in patients with insulin-dependent diabetes. Computer Methods and Programs in Biomedicine, 1996, 50, 241-246.	2.6	19
291	ISEC: a program to calculate insulin secretion. Computer Methods and Programs in Biomedicine, 1996, 50, 253-264.	2.6	150
292	Acid-base chemistry of the blood â€" a general model. Computer Methods and Programs in Biomedicine, 1996, 51, 107-119.	2.6	4
293	Quantitative Measurement of 3-O-Methyl-D-glucose by Gas Chromatography-MassSpectrometry as a Measure of Glucose TransportIn Vivo. , 1996, 31, 961-966.		34
294	Effects of Intravenous Infusion of Lipid-Free Apo A-I in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1203-1214.	1.1	80
295	How to measure insulin secretion. Diabetes/metabolism Reviews, 1994, 10, 91-117.	0.2	66
296	Computers in diabetes. Computer Methods and Programs in Biomedicine, 1994, 41, 151-152.	2.6	13
297	A probabilistic approach to glucose prediction and insulin dose adjustment: description of metabolic model and pilot evaluation study. Computer Methods and Programs in Biomedicine, 1994, 41, 153-165.	2.6	112
298	A simulation study to determine optimal insulin priming during glucose clamp studies. Computer Methods and Programs in Biomedicine, 1994, 41, 231-241.	2.6	2
299	Risk calculation of type 2 diabetes. Computer Methods and Programs in Biomedicine, 1994, 41, 297-303.	2.6	8
300	Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM. American Journal of Physiology - Endocrinology and Metabolism, 1993, 265, E162-E175.	1.8	33
301	Causal probabilistic network modelingâ€"illustration of its role in the management of chronic diseases. IBM Systems Journal, 1992, 31, 635-648.	3.1	32
302	Identification of insulin receptor systems: Assessing the impact of model selection and measurement error on precision of parameter estimates using monte carlo study. Journal of Theoretical Biology, 1991, 151, 367-383.	0.8	3
303	A Model-Based Approach to Insulin Adjustment. Lecture Notes in Medical Informatics, 1991, , 239-248.	0.1	40
304	A Validation Methodology for Testing Decision-Support Systems for Insulin Dosage Adjustment. Lecture Notes in Medical Informatics, 1991, , 382-388.	0.1	3
305	Consultation System for Insulin Dosage Adjustment. Lecture Notes in Medical Informatics, 1991, , 1044-1044.	0.1	0
306	Ten Years of Computer Support in a Metabolic Intensive Care Unit. Lecture Notes in Medical Informatics, 1991, , 930-933.	0.1	0

#	Article	IF	Citations
307	Computer models of albumin and haemoglobin glycation. Computer Methods and Programs in Biomedicine, 1990, 32, 259-263.	2.6	14
308	A consultation system for insulin therapy. Computer Methods and Programs in Biomedicine, 1990, 32, 303-310.	2.6	33
309	A Causal Probabilistic Network Model Of Carbohydrate Metabolism For Insulin Therapy Adjustment. , 0, , .		1
310	Strategies For Insulin Dosage Adjustment Using Model-based Blood Glucose Prediction. , 0, , .		0
311	The role of a diabetic advisory system (dias) in the management of insulin-dependent diabetes mellitus. , 0, , .		8
312	Modeling interstitial glucose kinetics in subjects with type I diabetes during physiological conditions. , 0, , .		0